Actively Recruiting
CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)
Led by University of Missouri-Columbia · Updated on 2025-10-15
72
Participants Needed
1
Research Sites
203 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand/forearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion/exclusion criteria. For inclusion, participants will be \>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and/or systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+/-2, day 14+/-2, and day 30+/-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand/forearm will be assessed for correlations with infections.
CONDITIONS
Official Title
CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years of age or older
- Bitten by a cat
- Bite located on the hand or forearm (below the elbow)
- Presenting to care within 24 hours of the cat bite
- Able to speak English
You will not qualify if you...
- Active local or systemic infection at the bite site (including pus, redness, and swelling)
- Fever higher than 100.4°F (38°C)
- Antibiotic use within the past 30 days
- Unwillingness to take study medication
- Unwillingness to attend follow-up visits or complete study forms
- Pregnancy
- Allergy to any study medication
- Immunocompromised conditions including primary and secondary immunodeficiencies such as ALPS, APS-1, BENTA, CEDS, CARD9 deficiency, cartilage-hair hypoplasia, Chédiak-Higashi syndrome, CGD, CVID, complement deficiencies, congenital neutropenia syndromes, CTLA4 deficiency, cyclic neutropenia, DiGeorge syndrome, DOCK8 deficiency, GATA2 deficiency, glycosylation disorders with immunodeficiency, HIES, hyper-IgM syndromes, interferon gamma, interleukin 12 and 23 deficiencies, LAD types 1 and 2, LRBA deficiency, PI3-kinase disease, PLCG2-associated antibody deficiency and immune dysregulation, SCID, selective IgA deficiency, STAT3 dominant-negative and gain-of-function diseases, WHIM syndrome, WAS, XLA, XLP, MAGT1 deficiency, ZAP-70 deficiency
- Secondary immunodeficiencies including malnutrition, uncontrolled diabetes, chronic uremia, trisomy 21, immunosuppressive drug therapies, systemic lupus erythematosus, malignancy, active radiation therapy, bone marrow ablation, HIV, and hepatitis infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Missouri
Columbia, Missouri, United States, 65212
Actively Recruiting
Research Team
S
Stephen H Colbert, MD
CONTACT
K
Kevin M Klifto, DO, PharmD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here